What is one recommended use of metaproterenol?

Metaproterenol is a bronchodilator that primarily acts on the beta-2 adrenergic receptors in the lungs, causing relaxation of the smooth muscles and resulting in widened airways. This therapeutic action makes it particularly effective in managing conditions characterized by bronchospasm.

The recommended use of metaproterenol in respiratory therapy includes treating asthma exacerbations, making it beneficial for patients experiencing sudden worsening of asthma symptoms. Its short-acting bronchodilator properties allow for quick relief of bronchospasm. In individuals with chronic obstructive pulmonary disease (COPD), it can also provide symptom relief.

Using metaproterenol for chronic cough or respiratory failure in neonates is less common and typically not recommended as a primary treatment for such conditions. Chronic cough is not a direct indication for bronchodilators like metaproterenol, as the cause of the cough must be determined first. In neonates, respiratory failure management usually requires more complex interventions and often involves different classes of medications or mechanical support.

Given these points, the accurate recommended use of metaproterenol relates closely to its application in treating asthma exacerbation.